InsiderTrades

Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2024-04-02 00:00:00 ET · period of report 2024-03-31 · accession 0001140361-24-017377 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-04-02 2024-04-01 ADMA Kestenberg-Messina Kaitlin M. COO, SVP, Compliance A - Grant $0.00 +192.3K 304.5K +171% $0
D 2024-04-02 2024-03-31 ADMA Kestenberg-Messina Kaitlin M. COO, SVP, Compliance F - Tax $6.60 -2,085 112.2K -2% -$13.8K
D 2024-04-02 2024-04-01 ADMA Kestenberg-Messina Kaitlin M. COO, SVP, Compliance A - Grant $0.00 +300.3K 300.3K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-04-01 A A 192,320 $0.00 304,510 D — — (F3) These shares represent RSUs that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date. (F4) Includes, as of the transaction date, (i) 192,320 RSUs granted on April 1, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (3); and (ii) 112,190 shares acquired pursuant to the vesting of RSUs.
2 Common Common Stock 2024-03-31 F D 2,085 $6.60 112,190 D — — (F1) Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities. (F2) As of the transaction date, represents 112,190 shares of Common Stock acquired pursuant to the vesting of RSUs.
3 Derivative Stock Option (right to buy) 2024-04-01 A A 300,328 $0.00 300,328 D $6.54 · — to 2034-04-01 300,328 Common Stock (F5) The option vests over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date.